Online inquiry

IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8639MR)

This product GTTS-WQ8639MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8639MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6792MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ11434MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ3118MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ9390MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ5663MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ8950MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ6958MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ2103MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW